1
|
Aoyama K, Tachi T, Kubo S, Koyama A, Watanabe M, Aoyama S, Noguchi Y, Tanaka K, Yasuda M, Shibata A, Mizui T, Teramachi H. Probable effects of polypharmacy and equivalent doses of psychotropic drugs on prevalence of adverse drug events among psychiatric inpatients in a general hospital in Japan. Hum Psychopharmacol 2024; 39:e2890. [PMID: 38180732 DOI: 10.1002/hup.2890] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/22/2023] [Revised: 12/06/2023] [Accepted: 12/07/2023] [Indexed: 01/06/2024]
Abstract
OBJECTIVE In psychiatry, polypharmacy or high psychotropic drug doses increase adverse drug event (ADE) prevalence. However, the full relationship between polypharmacy and ADEs is unclear, and few studies have evaluated dose equivalents for psychotropic drugs for ADEs. Thus, we conducted a retrospective analysis to clarify the effects of polypharmacy and chlorpromazine (CP)-, diazepam (DAP)-, and imipramine- equivalent doses on all ADEs in inpatients. METHODS Psychiatric inpatients in a Japanese hospital from April 1, 2016 to March 31, 2018, were enrolled. ADE severity and causality were assessed. Multiple logistic regression analyses were performed to evaluate ADE risk factors. RESULTS Among 462 patients analyzed, out of 471 patients enrolled, 145 (31.4%) experienced ADEs. The causality assessment determined that "possible" was 96.5%. The most common ADEs were nervous system disorders (35%). Multiple logistic regression analyses indicated an increase in ADE prevalence with the number of drugs used (≥5; p = 0.026); CP-equivalent dose (p = 0.048); and endocrine, nutritional, and metabolic disorders (p = 0.045). DAP-equivalent dose; infectious and parasitic diseases; and injury, poisoning, and consequences of other external causes decreased ADE prevalence (p = 0.047, 0.022, and 0.021, respectively). CONCLUSIONS Avoiding polypharmacy in psychiatric inpatients and adjusting drug regimens to safe equivalent doses could reduce ADEs during hospitalization.
Collapse
Affiliation(s)
- Keisuke Aoyama
- Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu-shi, Gifu, Japan
| | - Tomoya Tachi
- Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu-shi, Gifu, Japan
- Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya-shi, Aichi, Japan
- Laboratory of Pharmaceutical Health Care and Promotion, Gifu Pharmaceutical University, Gifu-shi, Gifu, Japan
- Department of Pharmacy, Gifu Municipal Hospital, Gifu-shi, Gifu, Japan
| | - Satoaki Kubo
- Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu-shi, Gifu, Japan
| | - Aisa Koyama
- Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu-shi, Gifu, Japan
| | - Mayuko Watanabe
- Department of Pharmacy, Gifu Municipal Hospital, Gifu-shi, Gifu, Japan
| | - Satoshi Aoyama
- Department of Pharmacy, Gifu Municipal Hospital, Gifu-shi, Gifu, Japan
| | - Yoshihiro Noguchi
- Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu-shi, Gifu, Japan
| | - Kazuhide Tanaka
- Laboratory of Pharmaceutical Health Care and Promotion, Gifu Pharmaceutical University, Gifu-shi, Gifu, Japan
- Department of Pharmacy, Gifu Municipal Hospital, Gifu-shi, Gifu, Japan
| | - Masahiro Yasuda
- Laboratory of Pharmaceutical Health Care and Promotion, Gifu Pharmaceutical University, Gifu-shi, Gifu, Japan
- Department of Pharmacy, Gifu Municipal Hospital, Gifu-shi, Gifu, Japan
| | - Akihiko Shibata
- Department of Psychiatry, Gifu Municipal Hospital, Gifu-shi, Gifu, Japan
| | - Takashi Mizui
- Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu-shi, Gifu, Japan
- Department of Pharmacy, Gifu Municipal Hospital, Gifu-shi, Gifu, Japan
| | - Hitomi Teramachi
- Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu-shi, Gifu, Japan
| |
Collapse
|